Research programme: antisense CD40 inhibitors - Isis Pharmaceuticals/novosom AG
Latest Information Update: 23 Aug 2013
At a glance
- Originator Isis Pharmaceuticals
- Developer novosom AG
- Class Antisense oligonucleotides
- Mechanism of Action CD40 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Inflammation